The objective of this study
is to determine the number of patients who receive anti-retroviral medicinal
products (ARMs) and to assess the frequency of prescriptions depending on age,
gender and treatment regimen by evaluating German statutory health insurance
data.
We analysed a number of databases of several million customers of various
nationwide statutory sickness funds and extrapolated the results to the overall
population of the statutory health insurance. The number of HIV-positive
patients with ARMs varied considerably between the statutory sickness funds
analysed.
- The number of patients with HIV diagnosis receiving ARMs that are exclusively approved for HIV increased from about
- 23,262 in 2008 to
- 30,200 in 2010.
- For ARMs labelled for both, HIV and HIV/chronic hepatitis B, indications, we calculated about 34,032 patients for the year 2011.
- In about 24.2% of the cases with HIV-only and HIV plus HIV/chronic hepatitis B-approved ARMs no HIV-diagnosis was documented.
- Patients in this group were significantly younger and more often female as compared to patients with documented HIV diagnosis who received prescriptions of ARMs.
- 16.5% of the patients received treatment within the label for chronic hepatitis B.
- In 7.7% of the patients ARMs were used off-label for prophylaxis (10.0%), for hepatitis (65.0%) or for unknown reasons (25.0%).
- Hence, the number of people under ARMs was estimated to be below the 44,000 patients calculated for statutory sickness funds patients on the basis of prescription data in 2011.
- According to our analysis only 39,000 of those could have a documented HIV diagnosis
Below: Für die gesetzliche Krankenversicherung adjustiert hochgerechnete Alters- und Geschlechtsverteilung für Patienten mit dokumentierter Diagnose und ARM-Verordnungen. Krankenkassen B im Jahr 2011
Below: Verordnungshäufigkeit der ARM in Abhängigkeit von der HIV-Diagnose in Krankenkassendaten B. Anteile eingelöster Verordnungen in 1, in 2-3 oder in allen 4 Quartalen
Full article (in German) at: http://goo.gl/3dMpBT
By: Tomeczkowski J1, Mahlich J2, Stoll M3.
1Janssen-Cilag GmbH, Abteilung Health Economics, Neuss,
Deutschland. Electronic address: jtomeczk@its.jnj.com.
2Janssen-Cilag GmbH, Abteilung Health Economics, Neuss,
Deutschland; Institut für Volkswirtschaftslehre, Universität Wien, Österreich.
3Klinik für Immunologie und Rheumatologie, Zentrum
Innere Medizin, Medizinische Hochschule Hannover, Hannover, Deutschland.
Z Evid Fortbild Qual Gesundhwes. 2015;109(8):594-604. doi: 10.1016/j.zefq.2014.09.002. Epub 2014 Nov 29.
More at: https://twitter.com/hiv
insight
No comments:
Post a Comment